Internal Medicine, Medical Oncology · Eugene, OR
NPI
1659596179
Since 2007
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
520 Country Club Pkwy
Eugene, OR, 97401
Phone (541) 683-5001
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.8M
147,195 services
Medicare patients, 2024
712
Average age 74
Drug cost, 2024
$9.5M
1,567 prescriptions
Company payments, 2025
$43K
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jeff P Sharman was code J9144 (injection, daratumumab, 10 mg and hyaluronidase-fihj), 12,420 times for 13 patients. In total Jeff P Sharman billed 147,195 services in 174 codes, and Medicare paid $2.8M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-08-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 12,420 | 13 | $38.77 | $482K |
| J0185 Injection, aprepitant, 1 mg | Office | 10,790 | 44 | $1.34 | $14K |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 8,250 | 11 | $0.88 | $7,230 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 7,590 | 11 | $2.34 | $18K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 7,300 | 21 | $44.58 | $325K |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 3,691 | 23 | $36.82 | $136K |
| Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 3,600 | 22 | $16.12 | $58K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2,700 | 14 | $0.10 | $271 |
| 36415 Venipuncture Blood Collection | Office | 1,274 | 451 | $8.62 | $11K |
| 85025 Blood Count | Office | 1,272 | 448 | $7.59 | $9,656 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,270 | 59 | $0.09 | $113 |
| 80053 Clinical Chemistry | Office | 1,244 | 447 | $10.32 | $13K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 891 | 53 | $0.74 | $660 |
| 83615 Clinical Chemistry | Office | 876 | 323 | $5.90 | $5,172 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 620 | 31 | $0.25 | $156 |
By year: 2022 $1.7M for 106,802 services; 2023 $1.7M for 98,508 services; 2024 $2.8M for 147,195 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,274 | 451 | $8.62 | $11K |
| 85025 Blood Count | 1,272 | 448 | $7.59 | $9,656 |
| 80053 Clinical Chemistry | 1,244 | 447 | $10.32 | $13K |
| 83615 Clinical Chemistry | 876 | 323 | $5.90 | $5,172 |
| 83520 Immunoassay | 432 | 87 | $16.93 | $7,312 |
| 82784 Immunoassay | 202 | 87 | $9.11 | $1,840 |
| 82728 Clinical Chemistry | 114 | 81 | $13.36 | $1,523 |
| 83540 Clinical Chemistry | 108 | 78 | $6.34 | $685 |
| 83550 Clinical Chemistry | 108 | 78 | $8.57 | $926 |
| 84550 Clinical Chemistry | 66 | 16 | $4.43 | $292 |
Medicare prescription drug claims, 2024
In 2024, the drug Jeff P Sharman prescribed most often to Medicare patients was Brukinsa (Zanubrutinib), with 155 prescriptions and refills. In total Jeff P Sharman wrote 1,567 Medicare prescriptions that cost $9.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Brukinsa Zanubrutinib | 155 | 155 | 23 | $2.1M |
| Calquence Acalabrutinib Maleate | 130 | 130 | 19 | $1.9M |
| Acyclovir Generic | 113 | 265 | 33 | $2,805 |
| Lenalidomide Generic | 66 | 66 | 22 | $844K |
| Eliquis Apixaban | 65 | 69 | 14 | $40K |
| Ondansetron Hcl Generic | 53 | 53 | 36 | $688 |
| Anastrozole Generic | 38 | 82 | 12 | $848 |
| Revlimid Lenalidomide | 38 | 38 | Under 11 | $629K |
| Imbruvica Ibrutinib | 35 | 35 | Under 11 | $555K |
| Hydroxyurea Generic | 33 | 92 | 11 | $1,033 |
| Prednisone Generic | 32 | 59 | 18 | $328 |
| Dexamethasone Generic | 27 | 33 | 19 | $694 |
| Amlodipine Besylate Generic | 26 | 56 | Under 11 | $145 |
| Oxycodone Hcl Generic | 24 | 24 | 12 | $216 |
| Letrozole Generic | 24 | 71 | 11 | $673 |
Brand drugs: - claims; generic drugs: 881 claims; opioid claims: 71.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jeff P Sharman $43K ($32K in general payments such as food, travel and fees and $11K for research) from 20 companies. The largest payer was F. Hoffmann-La Roche AG with $8,643.
| Company | Payments | Amount |
|---|---|---|
| F. Hoffmann-La Roche AG ROG.SW | 12 | $8,643 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $7,666 |
| BeOne Medicines USA, Inc. ONC | 5 | $5,299 |
| E.R. Squibb & Sons, L.L.C. BMY | 3 | $4,703 |
| Janssen Global Services, LLC JNJ | 5 | $4,575 |
| Roche Products Limited ROG.SW | 1 | $3,280 |
| AstraZeneca UK Limited AZN | 4 | $2,993 |
| Abbvie Inc. ABBV | 4 | $2,973 |
| Lilly USA, LLC LLY | 1 | $1,350 |
| Genmab U.S., Inc. GMAB | 1 | $938 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.